XIANG Xidong
Professor
Email: [email protected]
Tel：18202123689
Research field：Cancer cells of origin and cancer immunology
Biography
Dr. Dongxi Xiang completed his Ph.D. in Molecular Biotechnology at Deakin University, Australia in 2015. He joined Brigham and Women’s Hospital and Harvard Medical School in September 2015 as a Postdoc. Research Fellow and was promoted to Instructor in June 2018. Dr. Xiang investigated the biological and molecular mechanisms underlying breast cancer initiation and progression. Dr. Xiang is now a full Professor at Shanghai Cancer Institute and Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine. He is an Associate Chief Editor of Cellular Oncology (IF=7.05), and a Reviewer Board member for eBioMedicine (IF=11.2). Xiang Lab mainly integrates genetics, immunology and single-cell multi-omics to study cancer cells-of-origin, cancer developmental biology and mechanisms underlying cell fate change. Dr. Xiang has published more than 30 high-impact peer-reviewed papers in academic journals, including Cell, Nat. Communications, Theranostics, Med. Oncol.. Dr. Xiang also won multiple international awards, including the 2014 National Self-financed International Student Scholarship, Single Cell Genomics Pilot Award, Battelle Research Award, etc..
Publications
Wang H*, Xiang D*, Liu B, et al., Li Z#, Livingston D#. Inadequate DNA damage repair promotes mammary transdifferentiation leading to BRCA1 breast cancer. Cell 2019; 178(1):135-151.e19. (*co-first)
He A#, Huang Y, Cheng W, et al., Dong M#, Xiang D#. Organoid culture system for patient-derived osteosarcoma tissue. Medical Oncology 2020; 37(11):105. (#co-corresponding)
He A.#, Ma L., Huang Y., et al., Ren Sheng#, and Xiang D#. CDKL3 promotes osteosarcoma progression by activating Akt/PKB. Life Science Alliance 2020; 3; 5: 1-16. (#co-corresponding)
Xiang D, Tao L, Li Z. Modeling Breast Cancer Via an Intraductal Injection of Cre-Expressing Adenovirus into the Mouse Mammary Gland. J. Vis. Exp. 2019; 7; (148).
Xiang D, Shigdar S, Bean A, Bruce M, Yang W, Mathesh M, Wang T, Yin W, Tran Ha-Lien P, AlShamaileh H, Barrero RA, Zhang P, Li Y, Kong L, Liu K, Zhou S, Hou Y, He A, and Duan W. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Theranostics 2017; 7 (17): 4071.
